Gilles montalescot biography of donald

          Gilles Montalescot, MD, PhD. Head of the Department of Cardiology Institute of Cardiology Pitié-Salpêtrière University Hospital Paris, France.

        1. Gilles Montalescot from the Institut Cardiologie Paris, France to bring us this study pertaining to percutaneous coronary artery interventions.
        2. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research.
        3. The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke.
        4. Dr.

          5. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research.!

          CardioExchange Archive

          CardioExchange’s John Ryan, Rick Lange, and David Hillis interview Gilles Montalescot, lead investigator of the ACCOAST trial, about why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.

          The study, published in The New England Journal of Medicine, was presented at the European Society of Cardiology conference in Amsterdam.

          THE STUDY

          In a study funded by the manufacturer of prasugrel, researchers randomized 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo catheterization to receive either placebo or a 30-mg pre-angiography loading dose of prasugrel.

          The two groups did not differ significantly in the primary composite endpoint of death from cardiovascular causes, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa inhibitor rescue therapy through day 7.

          Major bleeding was significantly more commo